Lanthanum (La) is a rare-earth element in transition Group III b of the periodic table. It is a ductile and malleable, silvery-white metal, soft enough to be cut with a knife. Lanthanum carbonate (La2[CO3]3) is the most recent non-calcium, non-aluminum phosphate binder to be developed for the treatment of hyperphosphatemia. This drug has already been registered and available in the US and EU. Precilinical studies have shown that it is as effective as aluminium, without the associated toxicity, and is minimally absorbed. In clinical studies (La2[CO3]3) has a similar ability to calcium carbonate in controlling serum phosphate level without hypercalcemia. In this review I would like to summarize the pharmacodynamic and pharmacokinetic profile of this new phosphate binder (La2[CO3]3) which will be registered in our country in the near future.